Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Tucson, AZ
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Oxnard, CA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Oxnard, CA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Santa Monica, CA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Santa Rosa, CA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Wellington, FL
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Wellington, FL
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Atlanta, GA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Meridian, ID
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Meridian, ID
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Melrose Park, IL
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Melrose Park, IL
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Jeffersonville, IN
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Jeffersonville, IN
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Rockville, MD
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Rockville, MD
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Jefferson City, MO
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Jefferson City, MO
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Las Vegas, NV
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Hackensack, NJ
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
LawrenceVille, NJ
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
LawrenceVille, NJ
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Buffalo, NY
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Poughkeepsie, NY
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Poughkeepsie, NY
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Concord, NC
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Concord, NC
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Durham, NC
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Raleigh, NC
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Springfield, OR
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Springfield, OR
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Bala Cynwyd, PA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Lancaster, PA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Lancaster, PA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Myrtle Beach, SC
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Nashville, TN
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Salt Lake, UT
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Salt Lake, UT
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Fairfax, VA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Salem, VA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Salem, VA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Clinical Research Facility
mi
from
Burien, WA
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Clinical Research Facility
mi
from
Burien, WA
Click here to add this to my saved trials
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
mi
from
Ciudad Autonoma de Buenos Aires,
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Alaska Clinical Research Center, LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Southern California Permanente Medical Group
mi
from
Anaheim, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Southern California Permanente Medical Group
mi
from
Anaheim, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Southern California Permanente Medical Group
mi
from
Baldwin Park, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Southern California Permanente Medical Group
mi
from
Baldwin Park, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Southern California Permanente Medical Group
mi
from
BellFlower, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Southern California Permanente Medical Group
mi
from
BellFlower, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Pacific Clinical Center
mi
from
Beverly Hills, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Pacific Clinical Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
South County Hematology/Oncology
mi
from
Chula Vista, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
South County Hematology/Oncology
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Southern California Permanente Medical Group
mi
from
Fontana, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Southern California Permanente Medical Group
mi
from
Fontana, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Southern California Permanente Medical Group
mi
from
Irvine, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Southern California Permanente Medical Group
mi
from
Irvine, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Cancer Center Oncology Medical Group
mi
from
La Mesa, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Cancer Center Oncology Medical Group
mi
from
La Mesa, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
North County Oncology Medical Clinic Inc
mi
from
Oceanside, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
North County Oncology Medical Clinic Inc
mi
from
Oceanside, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
San Bernardino Urological Associates
mi
from
San Bernardino, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
San Bernardino Urological Associates
mi
from
San Bernardino, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urological Physicians of San Diego, Inc.
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urological Physicians of San Diego, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Southern California Permanente Medical Group
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Southern California Permanente Medical Group
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Medical Oncology Associates - SD
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Medical Oncology Associates - SD
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Sharp Memorial Hospital Investigational Pharmacy
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Sharp Memorial Hospital Investigational Pharmacy
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Sharp Rees-Stealy
mi
from
San Diego, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Sharp Rees-Stealy
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Pacific Clinical Research
mi
from
Santa Monica, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Pacific Clinical Research
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Agajanian Institute of Oncology and Hematology
mi
from
Whittier, CA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Agajanian Institute of Oncology and Hematology
mi
from
Whittier, CA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Porter Adventist Hospital
mi
from
Denver, CO
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urology Associates, PC
mi
from
Denver, CO
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urology Associates, PC
mi
from
Denver, CO
Click here to add this to my saved trials